Replication of the CARMELINA Diabetes Trial in Healthcare Claims

CompletedOBSERVATIONAL

Enrollment

101,830

Participants

Timeline

Start Date

September 22, 2017

Primary Completion Date

February 18, 2021

Study Completion Date

February 18, 2021

Conditions

Diabetes

Interventions

DRUG

Linagliptin

Linagliptin dispensing claim is used as the exposure

DRUG

Sulfonylurea

2nd generation sulfonylurea dispensing claim is used as the reference

Trial Locations (1)

Brigham & Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT03936036 - Replication of the CARMELINA Diabetes Trial in Healthcare Claims | Biotech Hunter | Biotech Hunter